ArticleGenes & cancer2011
Identification of c-Myb Target Genes in K562 Cells Reveals a Role for c-Myb as a Master Regulator.
Article in Genes & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Insights from pooled CRISPRi single-cell screens in K562 cells reveal gene functions, regulatory networks, and highlight opportunities and limitations.BMC genomics · 2026Article
- Creatine kinase B, a downstream effector of c-Myb, controls migration of osteosarcoma cells via regulation of N-cadherin.Cancer cell international · 2025Article
- MYB: A Key Transcription Factor in the Hematopoietic System Subject to Many Levels of Control.Advances in experimental medicine and biology · 2024Review
- Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML.Cell death & disease · 2023Article
- rs71327024 Associated with COVID-19 Hospitalization ReducesInternational journal of molecular sciences · 2023Article
- A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.Pathology oncology research : POR · 2022Article
- A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb.Journal of the American Chemical Society · 2021Article
- Chromatin occupancy and target genes of the haematopoietic master transcription factor MYB.Scientific reports · 2021Article
- Deciphering Master Gene Regulators and Associated Networks of Human Mesenchymal Stromal Cells.Biomolecules · 2020Article
- The mechanism of MYB transcriptional regulation by MLL-AF9 oncoprotein.Scientific reports · 2019Article
- Global Analysis of Enhancer Targets Reveals Convergent Enhancer-Driven Regulatory Modules.Cell reports · 2019Article
- c-Myb regulates tumorigenic potential of embryonal rhabdomyosarcoma cells.Scientific reports · 2019Article
- Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.Life science alliance · 2019Article
- MYB - A regulatory factor in hematopoiesis.Gene · 2018Review
- A c-Myb mutant causes deregulated differentiation due to impaired histone binding and abrogated pioneer factor function.Nucleic acids research · 2017Article
- Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer.Scientific reports · 2016Article
- c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia.Biomarker research · 2016Article
- MYB is a novel regulator of pancreatic tumour growth and metastasis.British journal of cancer · 2015Article
- c-Myb Binding Sites in Haematopoietic Chromatin Landscapes.PloS one · 2015Article
- Myb permits multilineage airway epithelial cell differentiation.Stem cells (Dayton, Ohio) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The c-Myb transcription factor is an important regulator of hematopoietic cell development. c-Myb is expressed in immature hematopoietic cells and plays a direct role in lineage fate selection, cell cycle progression, and differentiation of myeloid as well as B- and T-lymphoid progenitor cells. As a DNA-binding transcription factor, c-Myb regulates specific gene programs through activation of target genes. Still, our understanding of these programs is incomplete. Here, we report a set of novel c-Myb target genes, identified using a combined approach: specific c-Myb knockdown by 2 different siRNAs and subsequent global expression profiling, combined with the confirmation of direct binding of c-Myb to the target promoters by ChIP assays. The combination of these 2 approaches, as well as additional validation such as cloning and testing the promoters in reporter assays, confirmed that MYADM, LMO2, GATA2, STAT5A, and IKZF1 are target genes of c-Myb. Additional studies, using chromosome conformation capture, demonstrated that c-Myb target genes may directly interact with each other, indicating that these genes may be coordinately regulated. Of the 5 novel target genes identified, 3 are transcription factors, and one is a transcriptional co-regulator, supporting a role of c-Myb as a master regulator controlling the expression of other transcriptional regulators in the hematopoietic system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.